271 results on '"Felker, G"'
Search Results
2. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study
3. Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study
4. Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial
5. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
6. Serum Proteomic Analysis of Peripartum Cardiomyopathy Reveals Distinctive Dysregulation of Inflammatory and Cholesterol Metabolism Pathways
7. Electronic health record characterization and outcomes of heart failure with preserved ejection fraction
8. Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial
9. Circulating Angiokines Are Associated With Reverse Remodeling and Outcomes in Chronic Heart Failure
10. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society
11. Medication-Attributable Adverse Events in Heart Failure Trials
12. Trajectory of Decongestion and Mortality in Young Adults with Acute Heart Failure
13. Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan
14. Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel
15. Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status
16. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
17. A Randomized Controlled Trial of Mobile Health Intervention in Patients With Heart Failure and Diabetes
18. Diaphragmatic Function in Cardiovascular Disease: JACC Review Topic of the Week
19. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction
20. Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial
21. Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes
22. Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study
23. Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction
24. Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure
25. The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial
26. Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure
27. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF
28. Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure
29. Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy
30. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
31. Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure
32. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure
33. Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study
34. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
35. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
36. Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory
37. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction
38. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2
39. Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel
40. In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States
41. Splanchnic Nerve Block for Chronic Heart Failure
42. Endpoints in Heart Failure Drug Development: History and Future
43. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper
44. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF
45. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review
46. Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction
47. Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?
48. Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF
49. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction
50. Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.